SectorBiological Technology
Established Date11/11/1997
Listing Date05/09/2002
ExchangeNASDAQ Stock Exchange
Full-time Employees9
Fiscal Year Ends30/06
Security TypeDepository Receipts (Ordinary Shares)
Office addressLevel 14, 350 Collins Street, Melbourne, VIC 3000, Australia
BusinessThe company's business is to develop treatments for age-related diseases
IntroductionAlterity Therapeutics Limited was incorporated under the laws of the Commonwealth of Australia on 11 November 1997. The company is developing first-in-class therapies for the treatment of neurodegenerative diseases. The company's lead drug candidate, ATH 434 (formerly PBT 434), is the first of a new generation of small molecules designed to block the accumulation and aggregation of α-synuclein. Alpha-synuclein, when aggregated in the brain, is a pathological marker of Parkinson's disease and is considered an important biological target for the treatment of these neurodegenerative diseases.
